Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Nothing like some 'leaks' on the FDA Resubmission

<< Previous

Bullboard Posts

Next >>

Comment by houbahopon Apr 28, 2023 11:31am

69 Views

Post# 35419255

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA Resubmission

The easy thing to do here is to vote against 1 or 2 members of the board while voting in favor of all the others to send a clear message. If a couple of members receive 80%+ votes against while all the others receive 90%+ votes for, it would do the job, imo.

This is a way to send a clear signal to the BoD. They have to change the way they deal with their fiduciary duties towards their shareholders.

No clear message sent, expect business as usual for another year.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario